Opinion|Videos|November 12, 2025
Defining Future Needs for Real-World Evidence in mCRC
Panelists discuss how future RWE should expand to include survival, quality of life, and safety data to improve third-line mCRC care.
Advertisement
Episodes in this series
Panelists identify gaps in current evidence and the need for more comprehensive real-world data to guide third-line therapy in metastatic colorectal cancer (mCRC).
They suggest future real-world evidence (RWE) should capture not only survival outcomes but also patient-reported quality of life, adherence, and broader safety signals.
Such data could enhance treatment personalization and support health system adoption of evidence-based third-line strategies.
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
FDA Approves First Heart Valve to Keep Pace With Children's Growth
3
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5